Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients

Inclusion Criteria: Inclusion Criteria: * An Independent Ethics Committee (IEC)-approved written informed consent is signed and dated by the subject or by the legal representative * Subject/legal representative is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, and medication application according to the judgment of the investigator * Subject has Idiopathic Parkinson's Disease of more than 3 years' duration, defined by the cardinal sign, Bradykinesia, plus the presence of at least 1 of the following: resting tremor, rigidity, or impairment of postural reflexes, and without any other known or suspected cause of Parkinsonism * The investigator must observe the subject in both the 'on' and 'off' state and determine that the subject is Hoehn \& Yahr stage 2 through 4 in both the 'on' and 'off' state * Subject is male or female and aged ≥30 years at Screening (Visit 1) * Subject has a Mini Mental State Examination (MMSE) score of ≥25 at Screening (Visit 1) * Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with Benserazide or Carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline (Visit 2) * Subject is not adequately controlled on a L-dopa dose (in combination with Benserazide or Carbidopa) which was judged by the treating physician to be optimal * Subject must be willing and able to accurately co…